Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Denise A Yardley, M.D.
SCRI Development Innovations, LLC
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Aventura Medical Center
Aventura, Florida, United States
- Florida Cancer Specialists
Fort Myers, Florida, United States
- Watson Clinic Center for Cancer Care and Research
Lakeland, Florida, United States
- Medical Oncology Associates of Augusta
Augusta, Georgia, United States
- Northeast Georgia Medical Center
Gainesville, Georgia, United States
- Providence Medical Group
Terre Haute, Indiana, United States
- Mercy Hospital
Portland, Maine, United States
- Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
- National Capital Clinical Research Consortium
Bethesda, Maryland, United States
- St. Louis Cancer Care
Chesterfield, Missouri, United States
- Methodist Cancer Center
Omaha, Nebraska, United States
- Hematology Oncology Associates of Northern Nj
Morristown, New Jersey, United States
- Oncology Hematology Care
Cincinnati, Ohio, United States
- Cancer Centers of Southwest Oklahoma
Lawton, Oklahoma, United States
- South Carolina Oncology Associates, Pa
Columbia, South Carolina, United States
- Chattanooga Oncology Hematology Associates
Chattanooga, Tennessee, United States
- Family Cancer Center
Collierville, Tennessee, United States
- Tennessee Oncology
Nashville, Tennessee, United States
- South Texas Oncology and Hematology
San Antonio, Texas, United States
- Virginia Cancer Institute
Richmond, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2009
- Primary completion
- 31 Jul 2014
- Completion
- 31 Oct 2014
- Last update posted
- 22 Nov 2021
- Registered enrollment
- 168
- Registry id
- NCT00866905
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.